Prelude Therapeutics Inc (PRLD) — Titan Protect Analysis

PRLD

Prelude Therapeutics Inc

Healthcare · ·

$3.81

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$287M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.83

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-95.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$8.00

+110% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 3 analysts covering this stock

About Prelude Therapeutics Inc

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat M

https://preludetx.com

Country: United States Employees: 79 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.714

Good returns relative to risk taken

Kelly Fraction

0.0487

Modest edge detected — smaller position warranted

Calmar Ratio

0.045

Drawdown risk outweighs the returns — higher risk profile

Annual Return

4.1%

Historical annualised return based on price data

Max Drawdown

-90.4%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

125

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.10

Moves slightly more than the broader market

52W High

$5.54

31% below the year high

52W Low

$0.75

408% above the year low

Avg Volume

380,325

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.00

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

29.45

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-309.5%

Profit from core operations before interest and tax

Free Cash Flow

$-17,930,124

Negative — the business is spending more than it generates

Revenue (TTM)

$17M

Total revenue over the last 12 months

Net Income

$-77,798,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$10.00

Target Median

$8.00

Target Low

$6.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go